Tumor Suppression and Sensitization to Taxol Induced Apoptosis of E1A in Breast Cancer Cells
Abstract
The purpose of this project is to study the molecular mechanisms underlying ElA's proapoptotic effect and anti-tumor activity and to dissect the functional domains of ElA that are critical for its antitumor activity. Because a phase I E1A gene therapy protocol for human breast and ovarian cancers was completed and a phase II clinical trial is undergoing, we also plan to develop an alternative ElA mutant construct to maximize ElA therapeutic effects while minimizing its potential side-effects for cancer gene therapy. In trying to understand the mechanism underlying ElA's antitumor activity, we have found that ElA downregulated VEGF expression both in vitro and in vivo. We have also identified additional two new target genes that were critically involved in ElA-mediated chemosensitization. In addition to the proposed work we have also been trying to identify other molecules that may be regulated by ElA via the genomic and proteomic approaches. These studies can provide useful information for us to better understand the molecular functions of E1A, and hopefully we can use this knowledge to better design a mutant ElA construct for cancer gene therapy in the future.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2002
- Accession Number
- ADA407638
Entities
People
- Yong Liao
Organizations
- The University of Texas MD Anderson Cancer Center